Print ISSN:-2581-5555

Online ISSN:-2456-9542

CODEN : IIJCDU

Article History

Received : 24-03-2023

Accepted : 19-04-2023



Article Metrics




Downlaod Files

   


Article Access statistics

Viewed: 465

PDF Downloaded: 368


Endometrial cancer: Pathophysiology, diagnosis and management


Full Text PDF


Review Article

Author Details : Rohit R Doke*, Aditi R Lende, Shweta S Mule, Mrunal S Mahajan, Pranali Kulawade, Gayatri V Korde, Rutuja B Bhand

Volume : 8, Issue : 2, Year : 2023

Article Page : 80-85

https://doi.org/10.18231/j.ijcaap.2023.014



Suggest article by email

Get Permission

Abstract

The most prevalent gynecologic disease is cancer of the endometrium, In the US, it is the fourth most prevalent malignancy in women after breast, lung, and colorectal malignancies. Despite a steady prevalence of sickness, during the past 20 years, the death rate has climbed by more than 100%. The risk factors of endometrial cancer includes unopposed estrogen therapy, early menarche, late menopause, tamoxifen therapy, nulliparity, infertility or inability to ovulate, and polycystic ovarian syndrome. Ageing, obesity, hypertension, diabetes mellitus, and genetic nonpolyposis colorectal cancer are additional risk factors. This article presents an overview of endometrial carcinoma's epidemiology, prevention, diagnosis, therapy, and prognosis. Chemotherapy, radiation, surgery, and radiation therapy are all forms of treatment. Nonsurgical treatments can be used to treat endometrial hyperplasia with a low to moderate risk. The likelihood of survival is often determined by the disease stage and histology, with the majority of patients at stages I and II having a good prognosis. Endometrial cancer may be prevented in part by managing risk factors such obesity, diabetes, and hypertension.
 

Keywords: Chemotherapy, Management of EC, Pathophysiology, Surgical treatment



How to cite : Doke R R, Lende A R, Mule S S, Mahajan M S, Kulawade P, Korde G V, Bhand R B, Endometrial cancer: Pathophysiology, diagnosis and management. IP Int J Compr Adv Pharmacol 2023;8(2):80-85


This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.